Castration resistant prostate cancer
Drug research and approvals for castration resistant prostate cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 242 studies of castration resistant prostate cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 40 drug trials for it since 2013, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 242
- Trials authorized in Canada: 40
- FDA orphan approvals: 0
- EU medicines: 3
Recruiting Now
Newest start dates first, of 242 recruiting on ClinicalTrials.gov ↗- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and…NCT07667400 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Nov 19, 2026
- Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment…NCT07698535 · Phase 2 · University of Washington · starts Nov 15, 2026
- A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid TumorsNCT07887971 · Phase 1 · Aktis Oncology, Inc. · starts Nov 1, 2026
- JUR-003 in Adult Patients With Metastatic Prostate CancerNCT07824349 · Phase 1 · Juri Biosciences, Inc. · starts Oct 26, 2026
- Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical TherapyNCT07609225 · Early Phase 1 · University of Wisconsin, Madison · starts Oct 16, 2026
- GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate…NCT07871435 · Phase 1 / Phase 2 · GI Innovation, Inc. · starts Oct 12, 2026
- RYZ711 Diagnostic Platform StudyNCT07862582 · Phase 1 / Phase 2 · RayzeBio, Inc. · starts Oct 5, 2026
- Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer PatientsNCT06615752 · Phase 1 / Phase 2 · Charles Drew University of Medicine and Science · starts Oct 1, 2026
- Pluvicto Real-world Investigation in Survival in Metastatic CRPCNCT07697989 · Not reported · Novartis Pharmaceuticals · starts Oct 1, 2026
- AXT-1003 Combination With Enzalutamide in Participants With mCRPCNCT07897071 · Phase 1 · Axter Therapeutics (Beijing) Co., Ltd · starts Sep 24, 2026
Trials Authorized in Canada
The 10 newest of 40; search them all in Canada trials| Aug 4, 2026 | A phase 3, randomized, open-label study of rinzimetostat (oric-944) in combination with darolutamide compared with arpi or docetaxel in patients with…RINZIMETOSTAT (ORIC-944) / DAROLUTAMIDE | ORIC PHARMACEUTICALS, INC. | Pending |
| May 25, 2026 | An open-label, multi-center, first in human phase I global dose escalation and expansion study of inr731 single agent or in combination with arpi in patients…INR731 / ABIRATERONE / ENZALUTAMIDE | Novartis Pharmaceuticals Corporation | Ongoing |
| Jun 9, 2025 | A phase 1/2 first-time-in-human, open-label, multicenter, dose escalation and expansion study of gsk5458514 psma targeting t cell engager alone or in…GSK5458514 | GSK | Closed |
| May 22, 2025 | A multinational, multicenter, prospective, randomized, controlled, openlabel, phase 3 study of lutetium (177lu) rosopatamab tetraxetan in combination with…LUTETIUM (177LU) ROSOPATAMAB TETRAXETAN (177LU-TLX591) | TELIX INTERNATIONAL PTY LTD. | Ongoing |
| Feb 19, 2025 | Phase II clinical trial to test efficacy of targeting hypoxia combined with arsi after first-line arsi therapy for castrate resistant prostate cancer.EVOFOSFAMIDE (IMGS-101, TH-302) | UNIVERSITY HEALTH NETWORK | Pending |
| Feb 14, 2025 | A phase 3, two-part, randomized, open-label, adaptive study comparing bms- 986365 versus investigator's choice of therapy comprising either docetaxel or second…BMS-986365 / ABIRATERONE / ENZALUTAMIDE / DOCETAXEL / PREDNISONE | Bristol-Myers Squibb | Ongoing |
| Dec 16, 2024 | A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive…DOCETAXEL | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Jul 12, 2024 | Satisfaction: a phase I/ii, open-label, multi-center study of [225ac]ac-psma-r2 in men with heavily pre-treated psma positive metastatic castration resistant…[225AC]AC-PSMA-R2 (AAA802) / [68GA]GA-PSMA-R2 (AAA502) / GALLIUM (68GA)… | Novartis Pharmaceuticals Corporation | Ongoing |
| Jun 18, 2024 | Option-ddr: a randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration resistant prostate cancer patients with…CARBOPLATIN | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Jan 12, 2024 | [(a)c-225]-psma-62 phase I/ii (c)linical trial to (characterize (e)fficacy, safety, to(l)erability, and dosimetry in biochemically recurrent and metastatic…[AC-225]-PSMA-62 INJECTION | Eli Lilly | Ongoing |
Medicines Authorised in the EU
Newest first| Mar 27, 2020 | Nubeqadarolutamide | Bayer AG | EMA ↗ |
| Jan 14, 2019 | Erleadaapalutamide | Janssen-Cilag International NV | EMA ↗ |
| Sep 5, 2011 | Zytigaabiraterone | Janssen-Cilag International | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA